Next-generation immunotherapy biologics for glioblastoma

Ethan Schonfeld, Therese Sjöholm, Joe Ping Yiu Ha, Jun S. Liu, George Nageeb, Shreyas Annagiri, Lily Kim, John Choi, Michael LimFrontiers in Immunology 2026 · DOI

TL;DR

Glioblastoma (GBM) is notoriously resistant to immunotherapy, even with advanced treatments like checkpoint inhibitors. This review explores next-generation immunotherapies designed to overcome GBM's unique challenges, focusing on strategies that reprogram the tumor microenvironment and combine various biological approaches for better patient outcomes.

What Problem Does This Paper Address?

Despite the success of immunotherapies in other cancers, glioblastoma (GBM) remains a formidable challenge. The GBM tumor microenvironment (TME) is profoundly immunosuppressive, characterized by myeloid-driven suppression, a low number of tumor-specific mutations (neoantigens), significant internal variation within the tumor (intratumoral heterogeneity), and the ability of the tumor to adapt and resist treatment (adaptive resistance). These factors have led to a lack of survival benefit from standard anti-PD-1 monotherapy in clinical trials. This paper addresses the urgent need for novel therapeutic strategies that can effectively combat GBM by overcoming these inherent resistances.

Methods

This paper is a comprehensive review of existing and emerging immunotherapy biologics for GBM. It synthesizes information from preclinical studies and clinical trials, categorizing the approaches into several key areas:

  • Immune Checkpoint Combinations: Exploring how combining checkpoint inhibitors with other therapies can enhance their efficacy.
  • Cytokine and Immunomodulatory Proteins: Discussing biologics designed to alter the signaling environment within the TME to promote anti-tumor immunity.
  • Adoptive Cell Therapies: Reviewing engineered immune cells, such as CAR T-cells, designed to directly target and kill GBM cells.
  • Vaccines: Examining therapeutic vaccines aimed at stimulating a tumor-specific immune response.
  • Oncolytic Viruses: Investigating viruses engineered to selectively infect and destroy GBM cells while also triggering an immune response.

The review highlights key preclinical insights and emerging clinical trial results for each category, providing a broad overview of the therapeutic landscape.

Datasets

Not discussed in the paper. This is a review article, synthesizing existing research rather than presenting new experimental data.

Key Insights and Ideas

  • GBM's Unique Immunosuppressive Fortress: GBM isn't just "cold"; it actively builds a complex, multi-layered defense system involving myeloid cells, metabolic suppression, and physical barriers like the blood-brain barrier (BBB). This makes it fundamentally different from many other solid tumors.
  • Myeloid Cells are Key Players: The paper strongly emphasizes the central role of myeloid cells (MDSCs, TAMs, microglia) in driving GBM's immunosuppression. Targeting these cells is crucial for any effective immunotherapy.
  • Adaptive Resistance is a Major Hurdle: GBM tumors don't stay static. They adapt to therapies by upregulating alternative checkpoints, altering their genetic makeup, or even co-opting neural circuitry. This means single-target therapies are unlikely to succeed long-term.
  • Combinations are Essential: The consensus is clear: no single therapy is likely to be a silver bullet. Future success hinges on intelligently combining different approaches to tackle multiple resistance mechanisms simultaneously.
  • Beyond Traditional Checkpoints: While PD-1 and CTLA-4 are important, emerging targets like VISTA and LAG-3 are also being explored, offering new avenues for immune modulation.
  • Reprogramming the TME is the Goal: The focus is shifting from simply "activating" T cells to actively "reprogramming" the entire tumor microenvironment to be less hostile to anti-tumor immunity.
  • Neuron-Glioma Crosstalk: A fascinating emerging area is how GBM cells integrate into neural circuits, using electrical signals and synaptic connections to promote their own growth and invasion. Targeting this crosstalk is a novel therapeutic strategy.

Key Results

As a review, this paper doesn't present new quantitative results. Instead, it synthesizes findings from numerous studies:

  • Clinical Trial Landscape: Table 1 provides a detailed overview of phase II and III clinical trials, showcasing the diversity of agents being tested (vaccines, ICIs, CAR-T cells, etc.) and their outcomes (OS, PFS, ORR).
  • Limited Success of Monotherapy: The paper reiterates that anti-PD-1 monotherapy has not shown survival benefits in GBM.
  • Promising Preclinical Data: Many preclinical studies demonstrate significant tumor regression and survival benefits when combining different immunotherapeutic agents or combining them with standard treatments like radiation.
  • Early Clinical Signals: Some early-phase clinical trials show promise, with improved survival or disease stabilization in specific patient cohorts, but durable responses remain rare.

Limitations and Future Work

  • Translational Gap: A significant challenge is translating promising preclinical results from murine models to human GBM, as subtle differences in immune responses can have major impacts.
  • Complexity of the TME: The intricate and dynamic nature of the GBM TME, with its multiple overlapping immunosuppressive axes, makes it difficult to identify the most critical targets and optimal combination strategies.
  • Antigen Heterogeneity: GBM's inherent heterogeneity means that targeting a single antigen can lead to immune escape through antigen loss.
  • Need for Better Biomarkers: Improved tumor subtyping and immune profiling are crucial for identifying patients most likely to respond to specific therapies and for guiding combination strategies.
  • Future Directions: The authors emphasize the need for:
  • Longitudinal Profiling: Tracking tumor, CSF, and blood before and during treatment to understand dynamic immunosuppression and adaptive resistance.
  • Patient-Derived Organoids: Utilizing these models to predict adaptive responses and guide combination therapy selection.
  • Mechanistically Rational Combinations: Strategically combining therapies that address complementary resistance mechanisms (e.g., oncolytic viruses with CAR-T cells, or myeloid-directed therapies with checkpoint inhibitors).
  • High-Throughput Screening: Employing advanced techniques to test a vast number of potential cytokine combinations.

Summary updated

Abstract

Glioblastoma (GBM) remains largely resistant to immunotherapy despite the success of immune checkpoint inhibitors in other solid tumors. Phase III trials have not demonstrated survival benefit for anti-PD-1 monotherapy, likely reflecting the GBM tumor microenvironment’s profound myeloid-driven immunosuppression, low neoantigen burden, intratumoral heterogeneity, and adaptive resistance. These challenges have driven the development of next-generation immunotherapy biologics designed to reprogram the tumor microenvironment and overcome the innate and adaptive resistance of GBM. This review synthesizes advances in immunotherapy biologics including immune checkpoint combinations, cytokine and immunomodulatory proteins, adoptive cell therapies, vaccines, and oncolytic viruses, highlighting key preclinical insights and emerging clinical trial results. We conclude that improved tumor subtyping and immune profiling will be crucial to guide combination strategies that may achieve durable clinical benefit in GBM.
BibTeX
@inproceedings{schonfeld2026next,
  author = {Ethan Schonfeld and Therese Sjöholm and Joe Ping Yiu Ha and Jun S. Liu and George Nageeb and Shreyas Annagiri and Lily Kim and John Choi and Michael Lim},
  title = {{Next-generation immunotherapy biologics for glioblastoma}},
  booktitle = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1775093},
}
Figure